Recruiting
PHASE2
INTERVENTIONAL
NCT07128082
The Long COVID Treatment Trial
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
Name:
Placebo
Type:
DRUG
Description:
Participants in the control group will receive a placebo instead of active study medication for a 12 month period.
Primary Outcomes
Measure:
Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS)
TimeFrame:
12 months
Description:
The average difference in Fatigue Severity Scale (minimum score 9, maximum score 63, with higher scores indicating worse fatigue) between treatment and control groups of adults with Long COVID at month 3 or month 12 after study start
Trial Information
NCT ID
NCT07128082
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Scripps Translational Science Institute
Last Updated
December 15, 2025